Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Long-Term Growth Rate is Expected for the Neurological Disorder Drugs Market Between 2025 and 2034?

The market size for drugs treating neurological disorders has seen formidable growth in the previous years. The market, valued at $84.6 billion in 2024, is predicted to expand to $90.09 billion in 2025, signaling a compound annual growth rate (CAGR) of 6.5%. Factors influencing this growth during the historical period encompass an increase in animal experimentation yielding positive results, heightened therapeutic treatment interventions, rising occurrences of neurological issues, government-backed initiatives, and an uptick in healthcare spending.

The market size for drugs treating neurological disorders is projected to witness significant expansion in the next couple of years, reaching an impressive worth of $114.65 billion by 2029. This represents a compound annual growth rate (CAGR) of 6.2%. Several factors contribute to this upward trend during the forecasted period such as advances in personalized treatments and therapeutic options, emphasis on disease-modifying treatments, wider adoption of digital biomarkers, and the escalating rates of neurological diseases. Noteworthy trends within this period include improvements in drug development, breakthroughs in neuroimaging and genetic research, licensing partnerships and agreements, coupled with the rise of regenerative medicine.

Which Macro and Microeconomic Factors Are Accelerating the Growth of the Neurological Disorder Drugs Market?

The surge in instances of neurological diseases is anticipated to power the expansion of the neurological disorder drugs market. This span of ailments, affecting the brain, spine, and nerves, are the result of structural, biochemical, or electrical abnormalities, manifesting in varied symptoms. The rise in neurological maladies can be traced back to an ageing global populace and an amplified exposure to environmental, metabolic, and lifestyle threats. Drugs specifically aimed at neurological disorders are pivotal in handling these convoluted conditions, providing symptom relief, hampering disease progression and enhancing long-term patient outcomes. As an example, the Australian Institute of Health and Welfare, a government agency based in Australia, predicted in September 2024 that by 2058, the number of individuals suffering from dementia in Australia would more than double from about 411,100 in 2023 to an estimated 849,300. This population will comprise roughly315,500 men and 533,800 women. Consequently, the burgeoning prevalence of neurological ailments is fuelling the expansion of the neurological disorder drugs market.

Explore Comprehensive Insights Into The Global Neurological Disorder Drugs Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

What Are the Key Firms That Are Driving Transformation in the Neurological Disorder Drugs Market?

Major companies operating in the neurological disorder drugs market are:

• F. Hoffmann-La Roche Ltd_x000D_

• Bayer AG_x000D_

• Sanofi S.A_x000D_

• AstraZeneca PLC_x000D_

• Abbott Laboratories_x000D_

What Current Trends in the Neurological Disorder Drugs Market Should Industry Players Pay Attention To?

Major pharmaceutical firms active in the neurological disorder drugs market are concentrating on creating innovative therapies using Ocrelizumab to boost treatment effectiveness, enhance patient results, and broaden therapy choices for those with multiple sclerosis. As a humanized monoclonal antibody, Ocrelizumab is utilised in medically treating multiple sclerosis (MS), a type of neurological condition. For instance, Roche Holding AG, a Swiss pharmaceutical enterprise, introduced Ocrevus (Ocrelizumab) in India in February 2024. This is a fresh disease-modifying therapy (DMT) for people with multiple sclerosis. Ocrevus, backed by over 10 years of clinical and real-world evidence, is the first-ever DMT to receive approval for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). As a monoclonal antibody, it targets CD20-positive B cells considered to be involved in the auto-immune assault on the nervous system in MS cases. It is used to address both forms of the disease, RRMS and PPMS, thus becoming the first drug to receive approval for these MS types. It is generally administered intravenously every six months and its clinical trials have demonstrated effectiveness in reducing disease activity and slowing down disability progression.

Secure Your Global Neurological Disorder Drugs Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

How Are the Key Segments of the Neurological Disorder Drugs Market Impacting Its Expansion and Revenue Streams?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegtments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

What Regions Are Driving Expansion in the Neurological Disorder Drugs Market?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Does the Definition of the Neurological Disorder Drugs Market Include?

Neurological disorder drugs refer to medications used to treat disorders of the nervous system. These disorders can affect the brain, spinal cord, and nerves throughout the body. The drugs aim to manage symptoms, slow the progression of the disorder, and improve the quality of life for individuals affected.

Browse Through More Similar Reports By The Business Research Company:

Myeloproliferative Disorders Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Neurological Biomarkers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Bleeding Disorders Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: